VATS Lobectomy (Lung Cancer Surgery)

VATS (Video-Assisted Thoracoscopic Surgery) lobectomy removes a cancerous lung lobe through 2-4 small incisions (1-4cm each) using a videoscope, compared to open thoracotomy which requires a 15-20cm incision and rib spreading. VATS offers 50% less narcotic use, 2-3 day hospital stay versus 5-7 days, faster return to activities, and equivalent oncologic outcomes per multiple meta-analyses.

Per SEER data and published literature, 5-year survival rates are: Stage IA: 83-94%, Stage IB: 64-69%, Stage II: 48-55%. Some series show VATS achieving 94% 5-year overall survival compared to 82% for open thoracotomy. Complete resection (R0) rates exceed 95% with equivalent lymph node harvesting to open surgery.

Ideal candidates have: early-stage NSCLC (stages I-II), tumors ≤5cm in peripheral location, FEV1 >60% predicted, DLCO >40%, no chest wall invasion, and ability to tolerate single-lung ventilation. There is no strict age limit; VATS is particularly beneficial for elderly patients (≥70 years) due to 28% complication rate versus 45% for thoracotomy per published data.

Key advantages include: shorter hospital stay (3-5 vs 6-7 days), less post-operative pain (50% less narcotic use), smaller scars and better cosmesis, reduced complications (6-34% vs higher for open), faster return to normal activities (2-4 weeks vs 4-8 weeks for sedentary work), equivalent 5-year survival, and comparable lymph node staging per NCCN standards.

Typical hospital stay is 3-5 days, with some specialized centers achieving 1-2 day stays in >95% of patients. Discharge criteria include: chest tube removed (no air leak, drainage <200-400mL/24h), adequate pain control on oral medications, oxygen saturation >90% on room air, ambulatory status, and toleration of oral intake.

Most common: prolonged air leak (8-15%), atrial fibrillation (10-33%, especially in elderly). Other risks: pneumonia (3-10%), conversion to open surgery (6-11%), surgical site infection (1-3%), bleeding requiring transfusion (2-5%), DVT/PE (1-2% each). 30-day mortality is 0.3-1.3%, significantly lower than 2.3% for open thoracotomy.

Minimum 2-3 weeks post-surgery is recommended; ideal timing is 4-6 weeks for major thoracic surgery. Requirements before flying: chest tube removed, chest X-ray confirming full lung expansion, no air leak, stable condition. Per Aerospace Medical Association guidelines, 2-3 weeks after uncomplicated thoracic surgery with chest tube removal is acceptable. Business class recommended for recline ability.

Robotic-assisted thoracic surgery (RATS) using da Vinci Xi offers: enhanced 3D visualization, 360-degree instrument articulation, improved precision in anatomically challenging areas. Disadvantages: $2,000-5,000 premium cost, longer setup time. Oncologic outcomes (survival, lymph node harvest, R0 resection) are equivalent between RATS and conventional VATS per current literature.

Adjuvant therapy depends on final pathologic staging: Stage IA (≤4cm): observation only, no adjuvant therapy needed. Stage IB (>4cm): consider adjuvant chemotherapy (~5% absolute survival benefit). Stage II-IIIA: adjuvant platinum-based chemotherapy recommended. N2 disease: chemotherapy plus consider radiation. EGFR-positive tumors may receive osimertinib adjuvant therapy per current guidelines.

Conversion to open thoracotomy occurs in 6-11% of cases per national database studies. Primary causes: bleeding (37%), tumor advancement beyond VATS capability (30%), dense adhesions from prior surgery or radiation (23%). Conversion is not a failure but a safety measure; outcomes remain excellent when performed appropriately.

Thailand VATS lobectomy costs $16,900-$25,000 versus $45,000-$100,000 in the US (mean $45,080 ± $38,239 per CostHelper database 2024 and published US hospital cost studies), representing 60-80% savings. Thai pricing includes surgeon fees, hospital facility, 3-5 day stay, and international patient coordination. Additional costs: pre-operative workup $2,000-4,000, robotic surgery premium $2,000-5,000 if elected. Verify current rates directly with hospitals.

Essential documents: PET-CT scan (within 6 weeks), CT chest with contrast, biopsy pathology report confirming NSCLC, pulmonary function tests (FEV1, DLCO), recent labs (CBC, CMP, coagulation), cardiac evaluation (ECG, stress test if done), brain MRI if performed, complete medication list, insurance/ID documents, and advance directives.